Metabolic Diseases

Diabetes : Disruption of insulin action & glucose homeostasis

Diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin, when the body becomes resistant to insulin, or both. This results in elevated levels of blood glucose, which leads over time to serious damages to the heart, blood vessels, eyes, kidneys, and nerves. About 830 million people worldwide have diabetes, particularly in low- and middle-income countries, and more than 2 million deaths are directly attributed to diabetes each year. Several classes of antidiabetic agents have been developed and approved for the treatment of Type 1 diabetes and Type 2 diabetes, among which various insulin formulations, biguanides, incretin mimetics and SGLT-2 inhibitors. Despite the high number of antidiabetic treatments, a high medical need remains in order to improve the quality of life of the diabetic individuals.

of people affected 
worldwide

> 0 MM

Global Health costs
for diabetes

> 0 bn

pharmacological
treatments to date

> 0

Models

We have a long track record in conducting preclinical diabetes studies in the majority of commercially available rodent models. We offer a variety of established and validated rodent models of Type-1 diabetes and Type-2 diabetes for chronic efficacy and mechanisms of action studies.

Induced models

Prediabetic mouse models
DIO mouse models
DIO rat models
STZ-induced Type-1 Diabetes in rats/mice

Genetic models

db/db mice
DKD in db/db mice
ZDF rats
NOD mice

Methods

We master gold-standard methods to provide you with high-added value data about your health products’ efficacy and mechanisms of action on key hallmarks of diabetes such as food intake, body weight, circulating plasma biomarkers (Glucose, insulin, glucagon, HbA1c…). In addition, we offer complementary techniques that allow performing histological and genomic analyses on key tissues and organs.